找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Antiviral Drug Discovery and Development; Xinyong Liu,Peng Zhan,Vasanthanathan Poongavanam Book 2021 The Editor(s) (if applicable) and The

[復制鏈接]
樓主: 游牧
11#
發(fā)表于 2025-3-23 10:55:26 | 只看該作者
Covalent Antiviral Agents,tically increased. Hence, there is a pressing need to design potent broad-spectrum antiviral agents to treat a variety of viral infections and overcome viral resistance. Covalent inhibitors have the potential to achieve both goals owing to their biochemical efficiency, prolonged duration of action,
12#
發(fā)表于 2025-3-23 14:44:57 | 只看該作者
Safe-in-Man Broad Spectrum Antiviral Agents,als does not adequately allow for proper preparedness in the face of unknown future epidemics. In addition, drug developers lack the financial incentives to work on antiviral drug discovery, with most pharmaceutical companies choosing to focus on more profitable disease areas. Safe-in-man broad spec
13#
發(fā)表于 2025-3-23 22:05:33 | 只看該作者
Exploiting Ubiquitin Ligases for Induced Target Degradation as an Antiviral Strategy,tein that tags substrates with a single molecule or with a polyubiquitin chain. Monoubiquitination affects trafficking and signaling patterns of modified proteins. In contrast, polyubiquitination, particularly K48-linked polyubiquitination, targets the protein for degradation by the Ubiquitin-Protea
14#
發(fā)表于 2025-3-24 00:06:33 | 只看該作者
https://doi.org/10.1007/978-981-16-0267-2Antiviral drugs; enzyme inhibitors; drug design; antiviral therapy; viral infections
15#
發(fā)表于 2025-3-24 03:46:48 | 只看該作者
16#
發(fā)表于 2025-3-24 08:32:33 | 只看該作者
Antiviral Drug Discovery and Development978-981-16-0267-2Series ISSN 0065-2598 Series E-ISSN 2214-8019
17#
發(fā)表于 2025-3-24 12:43:39 | 只看該作者
18#
發(fā)表于 2025-3-24 15:05:54 | 只看該作者
19#
發(fā)表于 2025-3-24 20:38:07 | 只看該作者
20#
發(fā)表于 2025-3-25 00:32:34 | 只看該作者
https://doi.org/10.1007/978-3-319-02189-8 efforts during the last 40?years have led to the approval of over 30 antiretroviral drugs and the introduction of combination therapies that have turned HIV infection into a chronic but manageable disease. In this chapter, we provide an update on current available drugs and treatments, as well as f
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學 Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學 Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-31 09:20
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復 返回頂部 返回列表
忻城县| 将乐县| 陈巴尔虎旗| 长泰县| 沂水县| 聂拉木县| 南康市| 乐都县| 道真| 宁远县| 大化| 荃湾区| 久治县| 鲁山县| 民和| 六盘水市| 项城市| 麦盖提县| 黄石市| 枣强县| 西林县| 斗六市| 忻州市| 安福县| 航空| 南昌县| 吉隆县| 鄄城县| 宁强县| 商都县| 蒙城县| 繁昌县| 小金县| 行唐县| 五寨县| 育儿| 乐至县| 墨脱县| 当雄县| 灵台县| 革吉县|